Thymosin Alpha-1 vs VIP (Vasoactive Intestinal Peptide)

Thymosin Alpha-1: Thymic peptide with broad immunomodulatory activity, approved in over 35 countries. Typical dose 1000-1600 mcg. VIP (Vasoactive Intestinal Peptide): Broad neuropeptide with anti-inflammatory, immunomodulatory, and vasodilatory activity. Typical dose 50-200 (intranasal) mcg. Both fall under the Immune and Healing & Recovery categories.

Stacking Thymosin Alpha-1 with VIP (Vasoactive Intestinal Peptide) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Thymosin Alpha-1 is typically dosed: Twice weekly (SubQ) for Immune modulation; Twice weekly for Hepatitis treatment (clinical protocol); Daily for initial phase, then twice weekly for Acute immune support. VIP (Vasoactive Intestinal Peptide) is typically dosed: 4 sprays daily for Intranasal CIRS protocol (off-label); Per protocol for Research / immunomodulation.

Thymosin Alpha-1: Not FDA approved. Granted orphan drug designation for hepatocellular carcinoma and hepatitis B. Multiple clinical trials conducted but no NDA submitted. VIP (Vasoactive Intestinal Peptide): Not FDA approved as therapeutic. VIP analog aviptadil received Emergency Use Authorization consideration for COVID-19 ARDS but not full approval.